Successful treatment of Raynaud's Syndrome with prostacyclin

TY - JOUR

T1 - Successful treatment of Raynaud's Syndrome with prostacyclin

AU - Belch, J. J.

AU - Newman, P.

AU - Drury, J. K.

AU - Capell, H.

AU - Leiberman, P.

AU - James, W. B.

AU - Forbes, C. D.

AU - Prentice, C. R.

PY - 1981

Y1 - 1981

N2 - There is evidence to suggest that platelet activation occurs in Raynaud's syndrome. We evaluated the effect of prostacyclin (PGI2) a potent antiplatelet and vasodilator agent in 5 female patients with Raynaud's syndrome. Outpatient visits were made at weekly intervals for 4 weeks. At the first visit buffer solution (Wellcome Laboratories) was infused intravenously for 5 hrs, thereafter three five hr infusions of PGI2 at a peak dose of 10 ng/Kg/min were given. Six weeks after the infusions patients were reviewed. Symptomatic improvement, including healing of ischaemic ulcers, occurred in 4 out of 5 patients. Thermography confirmed an increase in hand temperature after PCI2. Subjective and objective improvement has persisted for at least 6 weeks after the last treatment.

AB - There is evidence to suggest that platelet activation occurs in Raynaud's syndrome. We evaluated the effect of prostacyclin (PGI2) a potent antiplatelet and vasodilator agent in 5 female patients with Raynaud's syndrome. Outpatient visits were made at weekly intervals for 4 weeks. At the first visit buffer solution (Wellcome Laboratories) was infused intravenously for 5 hrs, thereafter three five hr infusions of PGI2 at a peak dose of 10 ng/Kg/min were given. Six weeks after the infusions patients were reviewed. Symptomatic improvement, including healing of ischaemic ulcers, occurred in 4 out of 5 patients. Thermography confirmed an increase in hand temperature after PCI2. Subjective and objective improvement has persisted for at least 6 weeks after the last treatment.

M3 - Article

C2 - 7025341

SN - 0340-6245

VL - 45

SP - 255

EP - 256

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 3

ER -